Schering-Plough Product Pipeline

Worldwide Prescription Products

Schering-Plough Corporation
2000 Galloping Hill Road
Kenilworth, NJ 07033-0530

May 2005

Phase II

Adenosine 2a Receptor Antagonist
Parkinson's Disease

CCR5 Receptor Antagonist
HIV Infection

PDE 5 Inhibitor
Erectile Dysfunction

▶ **Pleconaril**
Common Cold and Asthma Exacerbations

Posaconazole
▶ I.V. Formulation

SARASAR
▶ Breast Cancer
Leukemia
Variety of Solid Tumors

TEMODAR
▶ I.V. Formulation
Variety of Solid Tumors

Phase III

ASMANEX
Chronic Obstructive Pulmonary Disease (COPD)

CLARINEX-D 12 Hour
Seasonal Allergic Rhinitis

CLARITIN/*Singulair* [2]
Seasonal Allergic Rhinitis

Garenoxacin
Variety of Gram-Positive/Gram-Negative Bacterial Infections

INTEGRILIN
Early Acute Coronary Syndrome

NASONEX
Rhinosinusitis

PEG-INTRON
Malignant Melanoma

Posaconazole
Prophylaxis

REMICADE [1]
Juvenile Idiopathic Arthritis
Pediatric Crohn's Disease
Psoriasis
Ulcerative Colitis

TEMODAR
▶ Brain Metastases
▶ Metastatic Melanoma

NDA/BLA/PLA/HRD Filed

Posaconazole
Serious Fungal Infections

JNDA Filed (Japan)

ZETIA
Lipid Lowering (Monotherapy)

▶ Phase advance ▶ Indication advance [1] International rights only [2] J.V. with Merck

Product Name	Market Size	Indications	U.S. Status	International Status
Adenosine 2a Receptor Antagonist Oral formulation	Prevalence in major world markets – 1.3 million Global market – $2.0 billion	Treatment of Parkinson's disease	Phase II	Phase II
ASMANEX Anti-inflammatory steroid Oral inhaler	Oral inhaled steroid market: U.S. market – $1.0 billion Int'l market – $1.9 billion	Dry powder inhaler (DPI) – COPD	Phase III	Phase III
CCR5 Receptor Antagonist Oral formulation	Market projections premature	Treatment of HIV infection	Phase II	Phase II
CLARINEX Nonsedating antihistamine Oral formulation	Oral antihistamine market: U.S. market – $3.2 billion Int'l market – $2.6 billion	Treatment of allergies: – CLARINEX-D 12 Hour	Phase III	Phase III
CLARITIN/*Singulair* Nonsedating antihistamine leukotriene inhibitor Oral formulation	U.S. allergy market – $6.9 billion	Dual-action approach to treating allergies – Seasonal allergic rhinitis	J.V. with MRK Phase III/Evaluating clinical program	U.S. only
Garenoxacin Quinolone antibiotic Oral, injectable formulations	Worldwide antibiotic market – $25.5 billion	Treatment of a variety of gram-positive/gram-negative bacterial infections	Phase III	Phase III
INTEGRILIN Glycoprotein IIb/IIIa platelet aggregation inhibitor Injectable formulation	Total U.S. patients with ACS – 550,000	Treatment of early acute coronary syndrome (ACS)	Phase III	Primarily U.S. rights
NASONEX Anti-inflammatory steroid Nasal inhaler	Nasal inhaled steroid market: U.S. market – $2.3 billion Int'l market – $789 million	Treatment of allergies: – Rhinosinusitis	Phase III	Phase III

Product Name	Market Size	Indications	U.S. Status	International Status
PDE 5 Inhibitor Oral formulation	Erectile dysfunction (ED) market: Estimated 150 million men worldwide have some degree of ED	Treatment of erectile dysfunction	Phase II	No studies planned
PEG-INTRON Long-acting antiviral/biological response modifier Injectable formulation	Worldwide interferon market – in excess of $2 billion	Cancer indications: – Malignant melanoma	Phase III	Phase III
Pleconaril Antiviral agent Intranasal formulation	Market projections premature	Treatment of common cold and asthma exacerbations	Phase II	Primarily U.S. rights
Posaconazole Triazole antifungal Oral, I.V. formulations	Worldwide antifungal market – in excess of $4.4 billion	Treatment of serious fungal infections – Prophylactic treatment of serious fungal infections – Intravenous formulation	NDA filed 5/04 Phase III Phase II	Filed in EU 7/04 Phase III Phase II
REMICADE Monoclonal antibody Injectable formulation	Worldwide Anti-TNF market – in excess of $5 billion	Treatment of inflammatory diseases: – Juvenile idiopathic arthritis – Pediatric Crohn's disease – Psoriasis – Ulcerative colitis	International only	Phase III Phase III Phase III Phase III
SARASAR Farnesyl transferase inhibitor Oral formulation	Market projections premature	Treatment of cancer: – Breast Cancer – Leukemia – Variety of solid tumors	Phase II Phase II Phase II	Phase II Phase II Phase II
TEMODAR Cytotoxic chemotherapeutic agent Oral, I.V. formulations	Alkylating agent market: U.S. market – $299 million Int'l market – $186 million	Treatment of cancer: – Brain Metastases – Metastatic melanoma – Variety of tumors – Intravenous formulation	Phase III Phase III Phase II Phase II	Phase III Phase III Phase II Phase II
ZETIA Lipid-lowering agent Oral formulation	Lipid-lowering market: Japan – approx. $2.4 billion	Dual-action approach to treating high cholesterol – Single tablet	J.V. w/MRK Approved 10/02	Co-market w/Bayer (Japan) Filed in Japan 10/03

Phase II

Pleconaril
New to this phase is the antiviral Plenconaril as a treatment of the common cold and asthma exacerbations. Schering-Plough has North American rights to the intranasal formulation from ViroPharma.

Posaconazole
An intravenous (IV) formulation is currently in development.

SARASAR
A new indication for breast cancer has been added to this phase.

TEMODAR
An IV formulation is currently in development.

Phase III

TEMODAR
Two new indications have been added to this phase: brain metastases and metastatic melanoma.

NDA/HRD filed

The Company has received U.S. regulatory approvals for ASMANEX (DPI) for asthma, CLARINEX-D 24 Hour for seasonal allergic rhinitis, NASONEX for polyposis and TEMODAR for first-line GBM. Therefore, these items have been removed from the *Product Pipeline*.

ASMANEX
An application in the EU for treatment of COPD has been withdrawn pending further discussions with EU regulatory authorities.

Posaconazole
An NDA was filed in the U.S. in May 2004. As previously disclosed, the FDA has requested an extension of their regulatory review. As a result, Schering-Plough now anticipates FDA action by the end of the first half of 2005.

Note:
As part of the current Phase II program for the **Adenosine 2a Receptor Antagonist** in Parkinson's disease, the company is reviewing several back up compounds to determine whether they offer a better profile than the original compound.

Garenoxacin
As previously announced, in June Schering-Plough and Toyama Chemical Co. Ltd. entered into a definitive licensing agreement for garenoxacin, Toyama's proprietary quinolone antibacterial agent in late-stage development. As a result of the agreement with Bayer, Schering-Plough expects it may need to sublicense rights to the Toyama product in the United States. The company is exploring its options with regard to garenoxacin and will continue to fulfill its commitments to Toyama under its arrangement, including taking the product through regulatory approval.

PDE 5 Inhibitor
As a result of the agreement with Bayer, Schering-Plough expects it may need to sublicense rights to the PDE 5 Inhibitor in the United States.

Recent Approvals

ASMANEX (DPI)
Asthma [U.S. 3/05]

CLARINEX-D 24 Hour
Seasonal Allergic Rhinitis [U.S. 3/05]

TEMODAR
First-Line GBM [U.S. 3/05]

NASONEX
Unscented [U.S. 8/04]
Polyposis [U.S. 12/04]

PEG-INTRON/REBETOL
Chronic Hepatitis C [Japan 10/04]

REMICADE
Psoriatic Arthritis [EU 10/04]

CLARINEX Syrup [U.S. 9/04]
Chronic Urticaria
Seasonal Allergic Rhinitis

VYTORIN[2] (ezetimibe/simvastatin)
Cholesterol Lowering [U.S. 7/04, Germany, Mexico 4/04]

REMICADE[1]
Early Rheumatoid Arthritis [EU 6/04]

REMICADE[1]
Maintenance of Fistulizing Crohn's Disease [EU 10/03]

PEG-INTRON REDIPEN
Hepatitis C [U.S. 10/03]

[1] International rights only [2] J.V. with Merck

Investor Contacts

Alex Kelly	(908) 298-7450
Janet M. Barth	(908) 298-7417

The SGP *Product Pipeline* is solely intended to provide to investors general information regarding Schering-Plough products in development and, for this reason, the information is not represented to be complete. Due to market factors and the nature of the development and approval process, the information – including the status of these products – is subject to change.

"International Status" does not necessarily imply that the company will be marketing the compound in all major countries.